EN DE
Watch MegaPro Biomedical Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

MegaPro Biomedical Co., Ltd (6827) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of MegaPro Biomedical Co., Ltd stock TWD 2.58, price TWD 15.25, that is 83.1% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006827009

MB MegaPro Biomedical Co., Ltd logo Thin data Nov 9, 2026

MegaPro Biomedical Co., Ltd

6827 · TWO
Weakest Setup

Our calculation puts a fair price 83% below what the stock costs today.

Ranks above peers (5/7)
Quality 45/100
Fair value 2.58 TWD · Strongly overvalued
Weak Growth (revenue YoY −22.2 %/yr in TWD)
Negative free cash flow
Narrow moat 18/100 · thin data
Thin data
⚠ Dilution
Watch MegaPro Biomedical Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

15.80 TWD 9.56 TWD Fair Value 2.58 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

11‑month range 9.56 TWD – 15.80 TWD · fair‑value band 1.71 TWD – 3.24 TWD · the 15.25 TWD price screens above the 2.58 TWD fair value. As of Nov 9, 2026.

Follow MegaPro Biomedical Co. in your weekly email

Every Wednesday you see whether MegaPro Biomedical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs.

Show moreShow less

It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor.

The company was founded in 2014 and is based in Zhubei, Taiwan.

Stock analysis

MegaPro Biomedical Co., Ltd (6827) currently trades at 15.25 TWD, while our model-based Fair Value estimate is 2.58 TWD, 83% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1.71 TWD (bear) to 3.24 TWD (bull), the price of 15.25 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

MegaPro Biomedical Co., Ltd reported revenue of 0 TWD in FY2025 versus 0 TWD in FY2021. Reported net income was −119M TWD in FY2025.

Key figures

Market cap 1.2B TWD (≈ $36.9M) Micro · EPS (TTM) −1.46 TWD · Return on assets (EBIT) −46.0% (5-year average) · Free cash flow −117M TWD · Net cash 82.0M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 3% below its 52-week high and 60% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −83%, 6827 screens richer than that median.

Fair Value models

Bear 1.71 TWD Fair Value 2.58 TWD Bull 3.24 TWD
Price 15.25 TWD · Downside -83.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 2.01 TWD 3.04 TWD 3.81 TWD 52
All 1 models by family
Asset-Based
NCAV (Graham) 2.01 TWD 3.04 TWD 3.81 TWD 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 80
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 65
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6827 screens overvalued: fair value 83% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare MegaPro Biomedical Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −83.1% · Bottom 25%
Profitability
Return on assets −42.7% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.14× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6827
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6827
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs 6827
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6827
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6827
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 6827
argenx SE ARGX $927.21 $908.40 −2% vs 6827
CSL Limited CSL A$200.77 A$183.04 −9% vs 6827
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 6827
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6827

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

MegaPro Biomedical Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "MegaPro Biomedical Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6827

Frequently asked questions

Is MegaPro Biomedical Co., Ltd (6827) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2.58 TWD versus a price of 15.25 TWD, about 83% lower (overvalued).
What is the fair value of 6827?
Our model-based fair value for MegaPro Biomedical Co., Ltd is 2.58 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 15.25 TWD.
What is the quality score of 6827?
MegaPro Biomedical Co., Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MegaPro Biomedical Co., Ltd (6827)?
Our model-based price target is the fair value of 2.58 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 1.71 TWD, optimistic scenario 3.24 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the MegaPro Biomedical Co., Ltd stock forecast for 2026?
Our models put fair value at 2.58 TWD, about 83% lower versus a price of 15.25 TWD (overvalued). Cautious scenario 1.71 TWD, optimistic scenario 3.24 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of MegaPro Biomedical Co., Ltd (6827)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MegaPro Biomedical Co., Ltd it is 2.58 TWD per share (as of Nov 9, 2026), against a price of 15.25 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is MegaPro Biomedical Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6827 trades above its calculated fair value: price 15.25 TWD, fair value 2.58 TWD, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6827?
No. The price is what the market pays today (15.25 TWD); the fair value is what the company's own numbers justify (2.58 TWD). For MegaPro Biomedical Co., Ltd the two are 12.67 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is MegaPro Biomedical Co., Ltd worth?
The market values MegaPro Biomedical Co., Ltd at about 1.2B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 15.25 TWD; our models calculate a fair value of 2.58 TWD per share.
What do the bullish and bearish scenarios say about 6827?
Our models span a range for MegaPro Biomedical Co., Ltd: cautious scenario 1.71 TWD, base 2.58 TWD, optimistic 3.24 TWD per share (as of Nov 9, 2026, price 15.25 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6827 from its 52-week high?
MegaPro Biomedical Co., Ltd trades at 15.25 TWD, about 3% below its 52-week high of 15.80 TWD and 60% above the low of 9.56 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2.58 TWD is for.
Which stocks are comparable to MegaPro Biomedical Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MegaPro Biomedical Co., Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 15.25 TWD, calculated fair value 2.58 TWD (−83%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6827 calculated?
We run MegaPro Biomedical Co., Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2.58 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. MegaPro Biomedical Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MegaPro Biomedical Co., Ltd (6827)?
The closing price on Nov 9, 2026 was 15.25 TWD. Our model-based fair value is 2.58 TWD, about 83% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MegaPro Biomedical Co., Ltd right now?
The price sits above even our optimistic bull case (3.24 TWD). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.71 TWD to 3.24 TWD) leaves room in how you read the outcome.

Key figures of MegaPro Biomedical Co., Ltd

How large is the market capitalisation of MegaPro Biomedical Co., Ltd (6827)?
The market capitalisation of MegaPro Biomedical Co., Ltd is 1.2B TWD (≈ $36.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of MegaPro Biomedical Co., Ltd (6827)?
Earnings per share at MegaPro Biomedical Co., Ltd are −1.46 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of MegaPro Biomedical Co., Ltd (6827)?
On an EBIT basis the return on assets of MegaPro Biomedical Co., Ltd is −46.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does MegaPro Biomedical Co., Ltd (6827) generate?
The free cash flow of MegaPro Biomedical Co., Ltd is −117M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does MegaPro Biomedical Co., Ltd (6827) hold?
MegaPro Biomedical Co., Ltd holds more cash than debt, 82.0M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch MegaPro Biomedical Co., Ltd in the live analysis

One click puts MegaPro Biomedical Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.